VivoSeq
Dermatology

Alopecia

28

Pipeline Programs↗

10

Active Trials↗

19

Companies Involved↗

Alopecia is an emerging landscape with 28 programs across 19 companies. The most active players are Suzhou Kintor Pharmaceutical Inc,, Cutia Therapeutics（Wuxi）Co.,Ltd, Viatris Specialty LLC. 5 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

25/100

Mech. Concentration

13/100

Completion Rate

86/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Suzhou Kintor Pharmaceutical Inc,

1 program

Phase 1C

Cutia Therapeutics（Wuxi）Co.,Ltd

1 program

Phase 1V

Viatris Specialty LLC

1 program

Phase 1M

Mitos Pharmaceuticals

1 program

Phase 2P

PDFE Pharma Innovations FZCO

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

32 of 35 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody26%Protein / enzyme13%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 100% of 41 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed19 · 50%
Unknown status6 · 16%
Not yet recruiting5 · 13%
Active, not recruiting3 · 8%
Recruiting2 · 5%
Terminated2 · 5%
Other1 · 3%

Clinical Trials

Trial Activity

38 trials

Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia
Recruiting·FFujian Medical University Union Hospital·N/A·NCT07373054·18 enrolled
Androgenic Alopecia TH07 Clinical Trial
Recruiting·TTriple Hair Inc·Phase 3·NCT07435012·420 enrolled
Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia
Active, not recruiting·NNorthwestern University·Phase 1·NCT03831334·14 enrolled
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
Active, not recruiting·ZZel Skin and Laser Specialists·Phase 2·NCT05456087·20 enrolled
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
Active, not recruiting·PPDFE Pharma Innovations FZCO·Phase 2·NCT07011485·15 enrolled
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Not yet recruiting·AApplied Biology, Inc.·Phase 3·NCT06762548·140 enrolled
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
Not yet recruiting·JJules Bordet Institute·Phase 2·NCT07474558·102 enrolled
Low Dose Oral Minoxdil in Androgenic Alopecia
Not yet recruiting·JJinnah Postgraduate Medical Centre·N/A·NCT07018349·76 enrolled
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
Not yet recruiting·EErasmus Medical Center·N/A·NCT07190534·50 enrolled
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Not yet recruiting·AApplied Biology, Inc.·Phase 1/2·NCT07397325·60 enrolled
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
Completed·SSuzhou Kintor Pharmaceutical Inc,·Phase 1·NCT04502901·40 enrolled
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
Completed·GGalderma R&D·N/A·NCT02460497·61 enrolled
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
Completed·—·N/A·NCT06202560·11 enrolled
Effectiveness of Apheresis Platelet-Rich Plasma Injection for Androgenic Alopecia
Completed·—·Phase 2·NCT07348315·201 enrolled
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
Completed·DDong-A ST Co., Ltd.·Phase 1·NCT02824380·14 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)